Expert view: Finding a translatable disease model suitable for drug discovery screening

For decades, target-based drug discovery has focused on biochemical assays or selected protein over-expression in immortalised cells to identify and optimise inhibitory or activating molecules. Only late during the drug development pipeline are molecules tested on more complex biological systems – typically in animals. However, animal experiments are costly and findings can translate poorly to humans.